Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01431274
Registration number
NCT01431274
Ethics application status
Date submitted
8/09/2011
Date registered
9/09/2011
Date last updated
16/07/2015
Titles & IDs
Public title
Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD)
Query!
Scientific title
A Randomised, Double-blind, Parallel Group Study to Assess the Efficacy and Safety of 52 Weeks of Once Daily Treatment of Orally Inhaled Tiotropium + Olodaterol Fixed Dose Combination (2.5 µg / 5 µg; 5 µg / 5 µg) (Delivered by the Respimat® Inhaler) Compared With the Individual Components (2.5 µg and 5 µg Tiotropium, 5 µg Olodaterol) (Delivered by the Respimat® Inhaler) in Patients With Chronic Obstructive Pulmonary Disease (COPD). [TOnado TM 1]
Query!
Secondary ID [1]
0
0
2009-010668-40
Query!
Secondary ID [2]
0
0
1237.5
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Pulmonary Disease, Chronic Obstructive
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - tiotropium + olodaterol
Treatment: Drugs - tiotropium
Treatment: Drugs - olodaterol
Treatment: Drugs - tiotropium
Treatment: Drugs - tiotropium + olodaterol
Treatment: Devices - Respimat
Experimental: tiotropium+olodaterol low dose FDC - Once daily 2 puffs solution for inhalation Respimat
Experimental: tiotropium+olodaterol high dose FDC - Once daily 2 puffs solution for inhalation Respimat
Active Comparator: olodaterol - Once daily 2 puffs solution for inhalation Respimat
Active Comparator: tiotropium low dose - Once daily 2 puffs solution for inhalation Respimat
Active Comparator: tiotropium high dose - Once daily 2 puffs solution for inhalation Respimat
Treatment: Drugs: tiotropium + olodaterol
fixed dose combination
Treatment: Drugs: tiotropium
low dose
Treatment: Drugs: olodaterol
one dose only
Treatment: Drugs: tiotropium
high dose
Treatment: Drugs: tiotropium + olodaterol
fixed dose combination
Treatment: Devices: Respimat
Respimat inhaler
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Intervention code [2]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3h) Response on Day 169.
Query!
Assessment method [1]
0
0
FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom. Number of participants analyzed are the number of patients contributing to the MMRM model in each treatment group.
Query!
Timepoint [1]
0
0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169.
Query!
Primary outcome [2]
0
0
Trough FEV1 Response on Day 170.
Query!
Assessment method [2]
0
0
Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FEV1 measurements performed at 23 h and at 23 h 50 min after inhalation of study medication at the clinic visit on the previous day.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
Query!
Timepoint [2]
0
0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23 h and at 23 h 50 min after inhalation of study medication on Day 170
Query!
Primary outcome [3]
0
0
Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)
Query!
Assessment method [3]
0
0
The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.
Query!
Timepoint [3]
0
0
Day 169
Query!
Secondary outcome [1]
0
0
Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)
Query!
Assessment method [1]
0
0
Mahler Transitional Dyspnoea Index (TDI) focal score on Day 169 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287) is the key secondary endpoint.
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.
Query!
Timepoint [1]
0
0
Day 169
Query!
Secondary outcome [2]
0
0
FEV1 AUC(0-3h) Response on Day 1
Query!
Assessment method [2]
0
0
FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
Query!
Timepoint [2]
0
0
1 hour (h) and 10 minutes (min) prior to dose to 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on the first day of randomized treatment.
Query!
Secondary outcome [3]
0
0
FEV1 AUC(0-3h) Response on Day 85
Query!
Assessment method [3]
0
0
FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
Query!
Timepoint [3]
0
0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 85 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 85.
Query!
Secondary outcome [4]
0
0
FEV1 AUC(0-3h) Response on Day 365
Query!
Assessment method [4]
0
0
FEV1 AUC(0-3h) was calculated as the area under the FEV1- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres. FEV1 AUC(0-3h) response was defined as FEV1 AUC(0-3h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
Query!
Timepoint [4]
0
0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 365 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 365.
Query!
Secondary outcome [5]
0
0
Trough FEV1 Response on Day 15.
Query!
Assessment method [5]
0
0
Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
Query!
Timepoint [5]
0
0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 15
Query!
Secondary outcome [6]
0
0
Trough FEV1 Response on Day 43
Query!
Assessment method [6]
0
0
Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
Query!
Timepoint [6]
0
0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 43.
Query!
Secondary outcome [7]
0
0
Trough FEV1 Response on Day 85
Query!
Assessment method [7]
0
0
Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
Query!
Timepoint [7]
0
0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1 hr and 10 min pre-dose on day 85.
Query!
Secondary outcome [8]
0
0
Trough FEV1 Response on Day 169
Query!
Assessment method [8]
0
0
Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
Query!
Timepoint [8]
0
0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1 hr and 10 min pre-dose on Day 169
Query!
Secondary outcome [9]
0
0
Trough FEV1 Response on Day 365
Query!
Assessment method [9]
0
0
Trough FEV1 was defined as the FEV1 value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FEV1 response was defined as trough FEV1 minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed
1 h and 10 min prior to administration of the first dose of randomised treatment at Day1.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
Query!
Timepoint [9]
0
0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 1 hr and 10 min pre-dose on day 365
Query!
Secondary outcome [10]
0
0
FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 1
Query!
Assessment method [10]
0
0
FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
Query!
Timepoint [10]
0
0
1 hour (h) and 10 minutes (min) prior to dose to 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on the first day of randomized treatment.
Query!
Secondary outcome [11]
0
0
FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 85
Query!
Assessment method [11]
0
0
FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC.Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
Query!
Timepoint [11]
0
0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 85 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 85.
Query!
Secondary outcome [12]
0
0
FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 169
Query!
Assessment method [12]
0
0
FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
Query!
Timepoint [12]
0
0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 169.
Query!
Secondary outcome [13]
0
0
FVC (Forced Vital Capacity) AUC(0-3h) Response on Day 365
Query!
Assessment method [13]
0
0
FVC AUC(0-3h) was calculated as the area under the FVC- time curve from 0 to 3 h post-dose using the trapezoidal rule, divided by the duration (3 h) to report in litres.
FVC AUC(0-3h) response was defined as FVC AUC(0-3h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
Query!
Timepoint [13]
0
0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 365 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h post-dose on Day 365.
Query!
Secondary outcome [14]
0
0
Trough FVC Response on Day 15.
Query!
Assessment method [14]
0
0
Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Query!
Timepoint [14]
0
0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 15
Query!
Secondary outcome [15]
0
0
Trough FVC Response on Day 43.
Query!
Assessment method [15]
0
0
Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Query!
Timepoint [15]
0
0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 10 min pre-dose on day 43
Query!
Secondary outcome [16]
0
0
Trough FVC Response on Day 85.
Query!
Assessment method [16]
0
0
Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Query!
Timepoint [16]
0
0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and on day 85
Query!
Secondary outcome [17]
0
0
Trough FVC Response on Day 170.
Query!
Assessment method [17]
0
0
Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours) and was calculated as the mean of the 2 FVC measurements performed at 23h and at 23h 50 min after inhalation of study medication at the clinic visit on the previous day.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted means (SE) were obtained from fitting an MMRM including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
Query!
Timepoint [17]
0
0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and at 23 h and at 23 h 50 min after inhalation of study medication on Day 170
Query!
Secondary outcome [18]
0
0
Trough FVC Response on Day 365.
Query!
Assessment method [18]
0
0
Trough FVC was defined as the FVC value at the end of the dosing interval (24 hours), calculated as the mean of the pre-dose measurements.
Trough FVC response was defined as trough FVC minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures (MMRM) model in each treatment group.
The adjusted means (SE) were obtained from fitting an Mixed effect model repeated measures (MMRM) including fixed effects of treatment, planned test day, treatment-by-test day interaction, baseline and baseline-by-test day interaction, patient as random effect, and spatial power covariance structure for within-patient errors and Kenward-Roger approximation for denominator degrees of freedom.
Query!
Timepoint [18]
0
0
1 h and 10 min prior to dose on the first day of randomized treatment (baseline) and on Day 365.
Query!
Secondary outcome [19]
0
0
FEV1 AUC(0-12h) Response in the Sub-set of Patients With 12-hour Pulmonary Function Test (PFT) on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)
Query!
Assessment method [19]
0
0
FEV1 AUC(0-12h) was calculated as the area under the FEV1- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
FEV1 AUC(0-12h) response was defined as FEV1 AUC(0-12h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.
Query!
Timepoint [19]
0
0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h post-dose on Day 169.
Query!
Secondary outcome [20]
0
0
FEV1 AUC(0-24h) Response in the Sub-set of Patients With 12-h PFTs on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)
Query!
Assessment method [20]
0
0
FEV1 AUC(0-24h) was calculated as the area under the FEV1- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres. FEV1 AUC(0-24h) response was defined as FEV1 AUC(0-24h) minus baseline FEV1. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.
Query!
Timepoint [20]
0
0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 23 h, 23 h and 50 min post-dose on Day 169.
Query!
Secondary outcome [21]
0
0
FVC AUC(0-12h) Response in the Sub-set of Patients With 12-h PFTs on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)
Query!
Assessment method [21]
0
0
FVC AUC(0-12h) was calculated as the area under the FVC- time curve from 0 to 12 h post-dose using the trapezoidal rule, divided by the duration (12 h) to report in litres.
FVC AUC(0-12h) response was defined as FVC AUC(0-12h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate. Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.
Query!
Timepoint [21]
0
0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h post-dose on Day 169.
Query!
Secondary outcome [22]
0
0
FVC AUC(0-24h) Response in Sub-set of Patients With 24-h PFTs on Day 169 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)
Query!
Assessment method [22]
0
0
FVC AUC(0-24h) was calculated as the area under the FVC- time curve from 0 to 24 h post-dose using the trapezoidal rule, divided by the duration (24 h) to report in litres.
FVC AUC(0-24h) response was defined as FVC AUC(0-24h) minus baseline FVC. Baseline was defined as the mean of the 2 pre-dose measurements performed 1 h and 10 min prior to administration of the first dose at visit 2 (day 1).
The adjusted mean (SE) were obtained from fitting an ANCOVA model with categorical effect of treatment and baseline as covariate.
Number of participants analyzed are the number of patients contributing to the ANCOVA model in each treatment group.
Query!
Timepoint [22]
0
0
1 hour (h) and 10 minutes (min) prior to dose to on the first day of randomized treatment and on Day 169 and 5 min, 15 min, 30 min, 1 h, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h, 23 h, 23 h and 50 min post-dose on Day 169.
Query!
Secondary outcome [23]
0
0
Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 85 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)
Query!
Assessment method [23]
0
0
The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.
Query!
Timepoint [23]
0
0
Day 85
Query!
Secondary outcome [24]
0
0
Saint George's Respiratory Questionnaire (SGRQ) Total Score on Day 365 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)
Query!
Assessment method [24]
0
0
The SGRQ is designed to measure health impairment in patients with COPD. It is divided into 2 parts: part 1 produces the symptoms score, and part 2 the activity and impacts scores. A total score is also produced. Each subscale score is the sum of the weights for the items in the subscale as a percent of the sum of the weights for a patient in the worst possible condition. The total score uses the same calculation except that the weights are summed over the entire questionnaire. The individual subscales as well as the total score can range from 0 to 100 with a lower score denoting a better health status. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.
Query!
Timepoint [24]
0
0
Day 365
Query!
Secondary outcome [25]
0
0
Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 43 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)
Query!
Assessment method [25]
0
0
Mahler Transitional Dyspnoea Index (TDI) focal score on Day 43 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.
Query!
Timepoint [25]
0
0
Day 43
Query!
Secondary outcome [26]
0
0
Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 85 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)
Query!
Assessment method [26]
0
0
Mahler Transitional Dyspnoea Index (TDI) focal score on Day 85 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome.
Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.
Query!
Timepoint [26]
0
0
Day 85
Query!
Secondary outcome [27]
0
0
Mahler Transitional Dyspnoea Index (TDI) Focal Score on Day 365 From the Two Twin Trials, Present 1237.5 (NCT01431274) and 1237.6 (NCT01431287)
Query!
Assessment method [27]
0
0
Mahler Transitional Dyspnoea Index (TDI) focal score on Day 365 From the Two Twin Trials, present 1237.5 (NCT01431274) and 1237.6 (NCT01431287).
The Mahler Dyspnoea questionnaire is an instrument which measures change from the baseline state The TDI focal score was used to measure the effect of Tio+Olo FDC on patients' dyspnoea after 24 weeks of treatment (Day 169). The focal score is the sum of the subscale scores for Functional Impairment, Magnitude of Effort and Magnitude of Task. Scores for each subscale range from -3 to 3 so that the Focal score ranges from -9 to 9. For all subscale scores and the Focal score a higher value indicates a better outcome. Number of participants analyzed are the number of patients contributing to the mixed effect repeated measures model (MMRM) in each treatment group.
Query!
Timepoint [27]
0
0
Day 365
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
1. Diagnosis of chronic obstructive pulmonary disease.
2. Relatively stable airway obstruction with post FEV1< 80% predicted normal and post
FEV1/FVC <70%.
3. Male or female patients, 40 years of age or older.
4. Smoking history of more than 10 pack years.
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
1. Significant disease other than COPD
2. Clinically relevant abnormal lab values.
3. History of asthma.
4. Diagnosis of thyrotoxicosis
5. Diagnosis of paroxysmal tachycardia
6. History of myocardial infarction within 1 year of screening visit
7. Unstable or life-threatening cardiac arrhythmia.
8. Hospitalization for heart failure within the past year.
9. Known active tuberculosis.
10. Malignancy for which patient has undergone resection, radiation therapy or
chemotherapy within last five years
11. History of life-threatening pulmonary obstruction.
12. History of cystic fibrosis.
13. Clinically evident bronchiectasis.
14. History of significant alcohol or drug abuse.
15. Thoracotomy with pulmonary resection
16. Oral ß-adrenergics.
17. Oral corticosteroid medication at unstable doses
18. Regular use of daytime oxygen therapy for more than one hour per day
19. Pulmonary rehabilitation program in the six weeks prior to the screening visit
20. Investigational drug within one month or six half lives (whichever is greater) prior
to screening visit
21. Known hypersensitivity to ß-adrenergic drugs, anticholinergics, BAC, EDTA
22. Pregnant or nursing women.
23. Women of childbearing potential not using a highly effective method of birth control
24. Patients who are unable to comply with pulmonary medication restrictions
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/09/2013
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
2624
Query!
Recruitment in Australia
Recruitment state(s)
SA,VIC
Query!
Recruitment hospital [1]
0
0
1237.5.61001 Boehringer Ingelheim Investigational Site - Toorak Gardens
Query!
Recruitment hospital [2]
0
0
1237.5.61002 Boehringer Ingelheim Investigational Site - Woodville
Query!
Recruitment hospital [3]
0
0
1237.5.61004 Boehringer Ingelheim Investigational Site - Frankston
Query!
Recruitment postcode(s) [1]
0
0
- Toorak Gardens
Query!
Recruitment postcode(s) [2]
0
0
- Woodville
Query!
Recruitment postcode(s) [3]
0
0
- Frankston
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Florida
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Illinois
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Louisiana
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Maine
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Maryland
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Michigan
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Nebraska
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
New York
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
North Carolina
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Ohio
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Oklahoma
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Pennsylvania
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Rhode Island
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
South Carolina
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Texas
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Virginia
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Washington
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
West Virginia
Query!
Country [22]
0
0
Argentina
Query!
State/province [22]
0
0
Buenos Aires
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Caba
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Capital Federal
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Cuidad Autonoma de Buenos Airess A
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
Mar del Plata
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Mendoza
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Monte Grande
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
Quilmes
Query!
Country [30]
0
0
Argentina
Query!
State/province [30]
0
0
Rosario
Query!
Country [31]
0
0
Argentina
Query!
State/province [31]
0
0
San Miguel de Tucuman
Query!
Country [32]
0
0
Argentina
Query!
State/province [32]
0
0
San Miguel de Tucuma
Query!
Country [33]
0
0
Bulgaria
Query!
State/province [33]
0
0
Plovdiv
Query!
Country [34]
0
0
Bulgaria
Query!
State/province [34]
0
0
Rousse
Query!
Country [35]
0
0
Bulgaria
Query!
State/province [35]
0
0
Shumen
Query!
Country [36]
0
0
Bulgaria
Query!
State/province [36]
0
0
Sofia
Query!
Country [37]
0
0
Bulgaria
Query!
State/province [37]
0
0
Troyan
Query!
Country [38]
0
0
Bulgaria
Query!
State/province [38]
0
0
Veliko Tarnovo
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
Alberta
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
British Columbia
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Manitoba
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Ontario
Query!
Country [43]
0
0
Canada
Query!
State/province [43]
0
0
Quebec
Query!
Country [44]
0
0
Canada
Query!
State/province [44]
0
0
Saskatchewan
Query!
Country [45]
0
0
China
Query!
State/province [45]
0
0
Beijing
Query!
Country [46]
0
0
China
Query!
State/province [46]
0
0
Changsha
Query!
Country [47]
0
0
China
Query!
State/province [47]
0
0
Foshan
Query!
Country [48]
0
0
China
Query!
State/province [48]
0
0
Guangzhou
Query!
Country [49]
0
0
China
Query!
State/province [49]
0
0
Nan Ning
Query!
Country [50]
0
0
China
Query!
State/province [50]
0
0
Shanghai
Query!
Country [51]
0
0
China
Query!
State/province [51]
0
0
Shenyang
Query!
Country [52]
0
0
China
Query!
State/province [52]
0
0
Wuhan
Query!
Country [53]
0
0
China
Query!
State/province [53]
0
0
Xi'An
Query!
Country [54]
0
0
China
Query!
State/province [54]
0
0
Yangzhou
Query!
Country [55]
0
0
China
Query!
State/province [55]
0
0
Yinchuan
Query!
Country [56]
0
0
Czech Republic
Query!
State/province [56]
0
0
Beroun
Query!
Country [57]
0
0
Czech Republic
Query!
State/province [57]
0
0
Cvikov
Query!
Country [58]
0
0
Czech Republic
Query!
State/province [58]
0
0
Praha 6
Query!
Country [59]
0
0
Czech Republic
Query!
State/province [59]
0
0
Rokycany
Query!
Country [60]
0
0
Czech Republic
Query!
State/province [60]
0
0
Znojmo
Query!
Country [61]
0
0
Denmark
Query!
State/province [61]
0
0
Aalborg
Query!
Country [62]
0
0
Denmark
Query!
State/province [62]
0
0
Hvidovre
Query!
Country [63]
0
0
Denmark
Query!
State/province [63]
0
0
Kolding
Query!
Country [64]
0
0
Denmark
Query!
State/province [64]
0
0
København NV
Query!
Country [65]
0
0
Denmark
Query!
State/province [65]
0
0
Næstved
Query!
Country [66]
0
0
Denmark
Query!
State/province [66]
0
0
Odense C
Query!
Country [67]
0
0
Denmark
Query!
State/province [67]
0
0
Roskilde
Query!
Country [68]
0
0
Denmark
Query!
State/province [68]
0
0
Silkeborg
Query!
Country [69]
0
0
Denmark
Query!
State/province [69]
0
0
Sønderborg
Query!
Country [70]
0
0
Denmark
Query!
State/province [70]
0
0
Vaerløse
Query!
Country [71]
0
0
Estonia
Query!
State/province [71]
0
0
Tallin
Query!
Country [72]
0
0
Estonia
Query!
State/province [72]
0
0
Tartu
Query!
Country [73]
0
0
Finland
Query!
State/province [73]
0
0
Helsinki
Query!
Country [74]
0
0
Finland
Query!
State/province [74]
0
0
Pori
Query!
Country [75]
0
0
Finland
Query!
State/province [75]
0
0
Turku
Query!
Country [76]
0
0
France
Query!
State/province [76]
0
0
Bethune Cedex
Query!
Country [77]
0
0
France
Query!
State/province [77]
0
0
Montpellier cedex 5
Query!
Country [78]
0
0
France
Query!
State/province [78]
0
0
Nantes
Query!
Country [79]
0
0
France
Query!
State/province [79]
0
0
Nîmes cedex 9
Query!
Country [80]
0
0
France
Query!
State/province [80]
0
0
Perpignan
Query!
Country [81]
0
0
France
Query!
State/province [81]
0
0
Saint Pierre Cedex
Query!
Country [82]
0
0
France
Query!
State/province [82]
0
0
Strasbourg
Query!
Country [83]
0
0
Germany
Query!
State/province [83]
0
0
Bamberg
Query!
Country [84]
0
0
Germany
Query!
State/province [84]
0
0
Berlin
Query!
Country [85]
0
0
Germany
Query!
State/province [85]
0
0
Erfurt
Query!
Country [86]
0
0
Germany
Query!
State/province [86]
0
0
Hamburg
Query!
Country [87]
0
0
Germany
Query!
State/province [87]
0
0
Koblenz
Query!
Country [88]
0
0
Germany
Query!
State/province [88]
0
0
Neu-Isenburg
Query!
Country [89]
0
0
Germany
Query!
State/province [89]
0
0
Oschersleben
Query!
Country [90]
0
0
Germany
Query!
State/province [90]
0
0
Rüdersdorf
Query!
Country [91]
0
0
Germany
Query!
State/province [91]
0
0
Weinheim
Query!
Country [92]
0
0
Germany
Query!
State/province [92]
0
0
Wiesloch
Query!
Country [93]
0
0
Guatemala
Query!
State/province [93]
0
0
Guatemala
Query!
Country [94]
0
0
Hungary
Query!
State/province [94]
0
0
Debrecen
Query!
Country [95]
0
0
Hungary
Query!
State/province [95]
0
0
Deszk
Query!
Country [96]
0
0
Hungary
Query!
State/province [96]
0
0
Kapuvar
Query!
Country [97]
0
0
Hungary
Query!
State/province [97]
0
0
Szombathely
Query!
Country [98]
0
0
Hungary
Query!
State/province [98]
0
0
Törökbalint
Query!
Country [99]
0
0
India
Query!
State/province [99]
0
0
Ahmedabad
Query!
Country [100]
0
0
India
Query!
State/province [100]
0
0
Bangalore
Query!
Country [101]
0
0
India
Query!
State/province [101]
0
0
Coimbatore
Query!
Country [102]
0
0
India
Query!
State/province [102]
0
0
Hyderabad
Query!
Country [103]
0
0
India
Query!
State/province [103]
0
0
Jaipur
Query!
Country [104]
0
0
India
Query!
State/province [104]
0
0
Mysore
Query!
Country [105]
0
0
India
Query!
State/province [105]
0
0
Pune
Query!
Country [106]
0
0
Italy
Query!
State/province [106]
0
0
Cagliari
Query!
Country [107]
0
0
Italy
Query!
State/province [107]
0
0
Genova
Query!
Country [108]
0
0
Italy
Query!
State/province [108]
0
0
Montescano (PV)
Query!
Country [109]
0
0
Italy
Query!
State/province [109]
0
0
Monza
Query!
Country [110]
0
0
Italy
Query!
State/province [110]
0
0
Parma
Query!
Country [111]
0
0
Italy
Query!
State/province [111]
0
0
Pisa
Query!
Country [112]
0
0
Japan
Query!
State/province [112]
0
0
Aoba-ku, Sendai, Miyagi
Query!
Country [113]
0
0
Japan
Query!
State/province [113]
0
0
Asahikawa, Hokkaido
Query!
Country [114]
0
0
Japan
Query!
State/province [114]
0
0
Bunkyo-ku, Tokyo
Query!
Country [115]
0
0
Japan
Query!
State/province [115]
0
0
Chuo-ku, Kumamoto, Kumamoto
Query!
Country [116]
0
0
Japan
Query!
State/province [116]
0
0
Gifu, Gifu
Query!
Country [117]
0
0
Japan
Query!
State/province [117]
0
0
Hakata-ku, Fukuoka, Fukuoka
Query!
Country [118]
0
0
Japan
Query!
State/province [118]
0
0
Hamamatsushi, Shizuoka
Query!
Country [119]
0
0
Japan
Query!
State/province [119]
0
0
Himeji, Hyogo
Query!
Country [120]
0
0
Japan
Query!
State/province [120]
0
0
Ikoma, Nara
Query!
Country [121]
0
0
Japan
Query!
State/province [121]
0
0
Inashiki-gun, Ibaraki
Query!
Country [122]
0
0
Japan
Query!
State/province [122]
0
0
Itabashi-ku, Tokyo
Query!
Country [123]
0
0
Japan
Query!
State/province [123]
0
0
Jonan-ku, Fukuoka, Fukuoka
Query!
Country [124]
0
0
Japan
Query!
State/province [124]
0
0
Kagoshima, Kagoshima,
Query!
Country [125]
0
0
Japan
Query!
State/province [125]
0
0
Kagoshima, Kagoshima
Query!
Country [126]
0
0
Japan
Query!
State/province [126]
0
0
Kamogawa, Chiba
Query!
Country [127]
0
0
Japan
Query!
State/province [127]
0
0
Kishiwada, Osaka
Query!
Country [128]
0
0
Japan
Query!
State/province [128]
0
0
Kitakyusyu,Fukuoka
Query!
Country [129]
0
0
Japan
Query!
State/province [129]
0
0
Koga, Fukuoka
Query!
Country [130]
0
0
Japan
Query!
State/province [130]
0
0
Komaki, Aichi
Query!
Country [131]
0
0
Japan
Query!
State/province [131]
0
0
Koshi, Kumamoto
Query!
Country [132]
0
0
Japan
Query!
State/province [132]
0
0
koto-ku, Tokyo
Query!
Country [133]
0
0
Japan
Query!
State/province [133]
0
0
Kuki, Saitama
Query!
Country [134]
0
0
Japan
Query!
State/province [134]
0
0
Kure, Hiroshima
Query!
Country [135]
0
0
Japan
Query!
State/province [135]
0
0
Kurume, Fukuoka
Query!
Country [136]
0
0
Japan
Query!
State/province [136]
0
0
Matsumoto, Nagano
Query!
Country [137]
0
0
Japan
Query!
State/province [137]
0
0
Matsusaka, Mie
Query!
Country [138]
0
0
Japan
Query!
State/province [138]
0
0
Minami-ku. Fukuoka, Fukuoka
Query!
Country [139]
0
0
Japan
Query!
State/province [139]
0
0
Morioka, Iwate
Query!
Country [140]
0
0
Japan
Query!
State/province [140]
0
0
Nagoya, Aichi
Query!
Country [141]
0
0
Japan
Query!
State/province [141]
0
0
Naka-gun, Ibaraki
Query!
Country [142]
0
0
Japan
Query!
State/province [142]
0
0
Okinawa, Urasoe
Query!
Country [143]
0
0
Japan
Query!
State/province [143]
0
0
Sayama, Osaka
Query!
Country [144]
0
0
Japan
Query!
State/province [144]
0
0
Sendai, Miyagi
Query!
Country [145]
0
0
Japan
Query!
State/province [145]
0
0
Seto, Aichi
Query!
Country [146]
0
0
Japan
Query!
State/province [146]
0
0
Shinagawa, Tokyo
Query!
Country [147]
0
0
Japan
Query!
State/province [147]
0
0
Shinjyuku-ku, Tokyo
Query!
Country [148]
0
0
Japan
Query!
State/province [148]
0
0
Takamatsu, Kagawa
Query!
Country [149]
0
0
Japan
Query!
State/province [149]
0
0
Wakayama, Wakayama
Query!
Country [150]
0
0
Japan
Query!
State/province [150]
0
0
Yanagawa-shi, Fukuoka,
Query!
Country [151]
0
0
Japan
Query!
State/province [151]
0
0
Yokohama, Kanagawa
Query!
Country [152]
0
0
Korea, Republic of
Query!
State/province [152]
0
0
Bucheon
Query!
Country [153]
0
0
Korea, Republic of
Query!
State/province [153]
0
0
Daegu
Query!
Country [154]
0
0
Korea, Republic of
Query!
State/province [154]
0
0
Seoul
Query!
Country [155]
0
0
Korea, Republic of
Query!
State/province [155]
0
0
Suwon
Query!
Country [156]
0
0
Korea, Republic of
Query!
State/province [156]
0
0
Wonju
Query!
Country [157]
0
0
Mexico
Query!
State/province [157]
0
0
Hermosillo
Query!
Country [158]
0
0
Mexico
Query!
State/province [158]
0
0
Mexico
Query!
Country [159]
0
0
Mexico
Query!
State/province [159]
0
0
Monterrey
Query!
Country [160]
0
0
Mexico
Query!
State/province [160]
0
0
Tijuana
Query!
Country [161]
0
0
Netherlands
Query!
State/province [161]
0
0
Almelo
Query!
Country [162]
0
0
Netherlands
Query!
State/province [162]
0
0
Breda
Query!
Country [163]
0
0
Netherlands
Query!
State/province [163]
0
0
Eindhoven
Query!
Country [164]
0
0
Netherlands
Query!
State/province [164]
0
0
Harderwijk
Query!
Country [165]
0
0
Netherlands
Query!
State/province [165]
0
0
Heerlen
Query!
Country [166]
0
0
Netherlands
Query!
State/province [166]
0
0
Hengelo
Query!
Country [167]
0
0
Netherlands
Query!
State/province [167]
0
0
Hoorn
Query!
Country [168]
0
0
Netherlands
Query!
State/province [168]
0
0
Nieuwegein
Query!
Country [169]
0
0
Netherlands
Query!
State/province [169]
0
0
Veldhoven
Query!
Country [170]
0
0
Netherlands
Query!
State/province [170]
0
0
Zutphen
Query!
Country [171]
0
0
New Zealand
Query!
State/province [171]
0
0
Dunedin
Query!
Country [172]
0
0
New Zealand
Query!
State/province [172]
0
0
Greenlane East Auckland NZ
Query!
Country [173]
0
0
Portugal
Query!
State/province [173]
0
0
Amadora
Query!
Country [174]
0
0
Portugal
Query!
State/province [174]
0
0
Coimbra
Query!
Country [175]
0
0
Portugal
Query!
State/province [175]
0
0
Lisboa
Query!
Country [176]
0
0
Portugal
Query!
State/province [176]
0
0
Porto
Query!
Country [177]
0
0
Portugal
Query!
State/province [177]
0
0
Vila Nova de Gaia
Query!
Country [178]
0
0
Portugal
Query!
State/province [178]
0
0
Viseu
Query!
Country [179]
0
0
Russian Federation
Query!
State/province [179]
0
0
Gatchina (Leningradskaya oblast)
Query!
Country [180]
0
0
Russian Federation
Query!
State/province [180]
0
0
Kazan
Query!
Country [181]
0
0
Russian Federation
Query!
State/province [181]
0
0
Moscow
Query!
Country [182]
0
0
Russian Federation
Query!
State/province [182]
0
0
St. Petersburg
Query!
Country [183]
0
0
Slovenia
Query!
State/province [183]
0
0
Golnik
Query!
Country [184]
0
0
Turkey
Query!
State/province [184]
0
0
Istanbul
Query!
Country [185]
0
0
Turkey
Query!
State/province [185]
0
0
Izmir
Query!
Country [186]
0
0
Turkey
Query!
State/province [186]
0
0
Izmit
Query!
Country [187]
0
0
Turkey
Query!
State/province [187]
0
0
Mersin
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Boehringer Ingelheim
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The overall objective of this study is to assess the efficacy and safety of 52 weeks once
daily treatment with orally inhaled tiotropium + olodaterol FDC (delivered by the RESPIMAT
Inhaler) compared with the individual components ( tiotropium, olodaterol) (delivered by the
RESPIMAT Inhaler) in patients with Chronic Obstructive Pulmonary Disease (COPD).
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01431274
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Boehringer Ingelheim
Query!
Address
0
0
Boehringer Ingelheim
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01431274
Download to PDF